Keytruda in combination with chemo, significantly reduced the risk of progression in Endometrial cancer

CAR-T Digest - August 2020

Weekly Digest - 25-31 Mar 2023

27 Mar 2023: KEYTRUDA (Pembrolizumab) (IV) / Stage III-IV or 1L Endometrial Carcinoma / Merck: Improved Progression-Free Survival in Phase 3 trial

Merck’s Phase 3 trial results of Keytruda plus chemo combination demonstrated statistically significant clinical improvement in PFS for the patients with 1L Endometrial Cancer
The KEYTRUDA regimen (Keytruda + Chemo vs Chemo) substantially reduced the risk of disease progression or death in the pMMR cohort of 591 evaluable patients after a median follow-up of 7.9 months
- median PFS: 13.1 months vs 8.7 months
The KEYTRUDA regimen (Keytruda + Chemo vs Chemo) significantly reduced the risk of disease progression or death in the dMMR cohort of 225 evaluable patients after a median follow-up of 12 months
- median PFS: Not reached vs 7.6 months
The safety profile of KEYTRUDA in this trial was consistent no new safety signals were identified
- Grade 3-5 adverse events (AEs) for pMMR cohort: 55.1% vs 45.3%
- Grade 3-5 adverse events (AEs) for dMMR cohort: 63.3% vs 47.2%
“Results from this trial show that KEYTRUDA plus chemotherapy, if approved, may represent an important new first-line immunotherapy option for patients with stage III-IV disease, and could extend the use of KEYTRUDA to more patients earlier in their treatment journey.” said Dr. Eliav Barr, Senior Vice President, head of global clinical development and chief medical officer